Cancers 2020, 12, 536
19 of 21
12. Ma, Q.-L.; Wang, J.-H.; Wang, Y.-G.; Hu, C.; Mu, Q.-T.; Yu, M.-X.; Wang, L.; Wang, D.-M.; Yang, M.; Yin,
X.-F.; et al. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute
myeloid leukemia. Int. J. Cancer 2015, 137, 1058–1065.
13. Bergaggio, E.; Piva, R. Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. Cancers 2019,
11, 563.
14. Molenaar, R.J.; Maciejewski, J.P.; Wilmink, J.W.; van Noorden, C.J.F. Wild-type and mutated IDH1/2
enzymes and therapy responses. Oncogene 2018, 37, 1949–1960.
15. Balss, J.; Meyer, J.; Mueller, W.; Korshunov, A.; Hartmann, C.; von Deimling, A. Analysis of the IDH1 codon
132 mutation in brain tumors. Acta Neuropathol. 2008, 116, 597–602.
16. Patel, K.P.; Ravandi, F.; Ma, D.; Paladugu, A.; Barkoh, B.A.; Medeiros, L.J.; Luthra, R. Acute Myeloid
Leukemia With IDH1 or IDH2 Mutation. Am. J. Clin. Pathol. 2011, 135, 35–45.
17. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin,
S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462,
739–744.
18. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.-H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.-T.; et al.
Oncometabolite 2-Hydroxyglutarate Is
a
Competitive Inhibitor of α-Ketoglutarate-Dependent
Dioxygenases. Cancer Cell 2011, 19, 17–30.
19. Losman, J.-A.; Looper, R.E.; Koivunen, P.; Lee, S.; Schneider, R.K.; McMahon, C.; Cowley, G.S.; Root, D.E.;
Ebert, B.L.; Kaelin, W.G. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects
Are Reversible. Science 2013, 339, 1621–1625.
20. Popovici-Muller, J.; Lemieux, R.M.; Artin, E.; Saunders, J.O.; Salituro, F.G.; Travins, J.; Cianchetta, G.; Cai,
Z.; Zhou, D.; Cui, D.; et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for
the Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 2018, 9, 300–305.
21. Liu, X.; Gong, Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomark. Res. 2019, 7, 22.
22. Okoye-Okafor, U.C.; Bartholdy, B.; Cartier, J.; Gao, E.N.; Pietrak, B.; Rendina, A.R.; Rominger, C.; Quinn,
C.; Smallwood, A.; Wiggall, K.J.; et al. New IDH1 mutant inhibitors for treatment of acute myeloid
leukemia. Nat. Chem. Biol. 2015, 11, 878–886.
23. Cho, Y.S.; Levell, J.R.; Liu, G.; Caferro, T.; Sutton, J.; Shafer, C.M.; Costales, A.; Manning, J.R.; Zhao, Q.;
Sendzik, M.; et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1
Inhibitor. ACS Med. Chem. Lett. 2017, 8, 1116–1121.
24. Pusch, S.; Krausert, S.; Fischer, V.; Balss, J.; Ott, M.; Schrimpf, D.; Capper, D.; Sahm, F.; Eisel, J.; Beck, A.-
C.; et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in
vivo. Acta Neuropathol. 2017, 133, 629–644.
25. Salituro, F.; Saunders, J. Therapeutically active compounds for use in the treatment of cancer characterized
as having an IDH mutation. Patent WO 2011/072174 A1 2011.
26. Chitneni, S.K.; Reitman, Z.J.; Gooden, D.M.; Yan, H.; Zalutsky, M.R. Radiolabeled inhibitors as probes for
imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl
sulfonamide analogs. Eur. J. Med. Chem. 2016, 119, 218–230.
27. Müller, B. a Imatinib and its successors--how modern chemistry has changed drug development. Curr.
Pharm. Des. 2009, 15, 120–133.
28. Shchemelinin, I.; Šefc, L.; Nečas, E. Protein kinases, their function and implication in cancer and other
diseases. Folia Biol. 2006, 52, 81–101.
29. Noronha, G.; Cao, J.; Chow, C.P.; Dneprovskaia, E.; Fine, R.M.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.;
Mak, C.C.; et al. Inhibitors of ABL and the ABL-T315I mutation. Curr. Top. Med. Chem. 2008, 8, 905–921.
30. Pemovska, T.; Johnson, E.; Kontro, M.; Repasky, G.A.; Chen, J.; Wells, P.; Cronin, C.N.; Mctigue, M.;
Kallioniemi, O.; Porkka, K.; et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding
conformation. Nature 2015, 519, 102–105.
31. Schoepfer, J.; Jahnke, W.; Berellini, G.; Buonamici, S.; Cotesta, S.; Cowan-Jacob, S.W.; Dodd, S.; Drueckes,
P.; Fabbro, D.; Gabriel, T.; et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine
kinase activity of BCR-ABL1. J. Med. Chem. 2018, 61, 8120–8135.
32. Chou, T.-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and
Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006, 58, 621–681.
33. Chou, T.C.T.-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay
Method. Cancer Res. 2010, 70, 440–446.